# Benzodiazepine-gebruik verhoogt risico op hartfalen en hospitalisatie — meta-analyse

*geplaatst 2026-10-13 · Hartfalen · Cardiovascular toxicology · doi 10.1007/s12012-026-10206-8 · https://hartvaat.nl/2026/10/05/benzodiazepine-gebruik-verhoogt-risico-op-hartfalen-en-hospitalisatie-meta-analy/*

Een systematische review en meta-analyse van elf studies toont aan dat benzodiazepine-gebruik gepaard gaat met een verhoogd risico op het ontstaan van hartfalen (HR 1,41) en hospitalisatie voor hartfalen (HR 1,29) vergeleken met niet-gebruik. Het risico op heropname lag ook hoger dan bij alternatieve slaapmiddelen zoals z-drugs, antipsychotica of suvorexant. Omdat de onderliggende studies grotendeels observationeel zijn, gaat het om associaties in plaats van causale verbanden. Cardiologen, huisartsen en internisten moeten benzodiazepines met de nodige voorzichtigheid voorschrijven bij patiënten met een verhoogd hartfalenrisico.

## English: Effects of Benzodiazepines on Heart Failure Outcomes and Adverse Events: A Systematic Review and Meta-Analysis.

A systematic review and meta-analysis of 11 observational studies found that benzodiazepine use is associated with a higher risk of developing heart failure (HR 1.41) and heart failure hospitalization (HR 1.29) compared to non-use. Risk of rehospitalization was also elevated relative to alternative hypnotics such as z-drugs, antipsychotics, and suvorexant. Given the observational nature of the included data, these findings reflect associations rather than causation. Clinicians should exercise caution when prescribing benzodiazepines for insomnia in patients with existing or elevated cardiovascular risk.

## Abstract (original, from the publication)

The effects of benzodiazepines (BZDs) for insomnia on heart failure (HF) remain unclear, particularly among high-risk populations. Relevant studies were retrieved by searching seven databases from inception to August 7, 2025. Hazard ratios (HRs) or risk ratios estimated for related HF outcomes were extracted. Meta-analyses were conducted using a random-effects model, and study quality was assessed using the Newcastle-Ottawa Scale (NOS). Eleven studies met the inclusion criteria, with follow-up durations ranging from 180 days to 15 years. The meta-analysis demonstrated that BZD use was associated with increased risks of HF incidence (HR = 1.41, 95% confidence interval (CI) 1.16-1.72) and HF hospitalization (HR = 1.29, 95% CI 1.01-1.65) compared to non-use. BZD use also suggested an increased risk of HF hospitalization and rehospitalization compared to antipsychotics, z-drugs, and suvorexant. Benzodiazepine use was associated with an increased risk of HF-related outcomes. Since most of the included studies were observational, these findings indicate associations rather than causal relationships. BZDs should be used with caution among populations at risk of HF when treating insomnia.

Auteurs: Yi-Sin Huang, Galuh Nawang Prawesti, Yi-Chun Chiang, Yang-Ching Chen, Hsiang-Yin Chen

---
Bron: Cardiovascular toxicology, https://doi.org/10.1007/s12012-026-10206-8. Bijgewerkt 2026-10-06T01:16:42Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.